Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
S. Vincent Rajkumar
American Journal of Hematology (2022) Vol. 97, Iss. 8, pp. 1086-1107
Open Access | Times Cited: 548

Showing 1-25 of 548 citing articles:

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 17, pp. 1597-1609
Closed Access | Times Cited: 55
Emerging role of exosomes in cancer therapy: progress and challenges
Jiale Li, Jiachong Wang, Zigui Chen
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Decoding the role of miRNAs in multiple myeloma pathogenesis: A focus on signaling pathways
Amr Mohamed Yehia, Elsayed G.E. Elsakka, Ahmed I. Abulsoud, et al.
Pathology - Research and Practice (2023) Vol. 248, pp. 154715-154715
Closed Access | Times Cited: 31
Encapsulation of Nano‐Bortezomib in Apoptotic Stem Cell‐Derived Vesicles for the Treatment of Multiple Myeloma
Zeyuan Cao, Peiyi Li, Yuzhen Li, et al.
Small (2023) Vol. 19, Iss. 40
Closed Access | Times Cited: 28
Targeting ABCB6 with nitidine chloride inhibits PI3K/AKT signaling pathway to promote ferroptosis in multiple myeloma
Zhao Yin, Yiwen Lv, Deng Li, et al.
Free Radical Biology and Medicine (2023) Vol. 203, pp. 86-101
Closed Access | Times Cited: 24
Chromosomal defects in multiple myeloma
Sarah E. Clarke, Kathryn A. Fuller, Wendy N. Erber
Blood Reviews (2024) Vol. 64, pp. 101168-101168
Open Access | Times Cited: 11
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives
Jingjing Pu, Ting Liu, Xuzhen Wang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Monoclonal Gammopathies
Rafael Ríos Tamayo
Elsevier eBooks (2024), pp. 358-374
Closed Access | Times Cited: 11
Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review
Nina Rosa Neuendorff, Abdullah Khan, Fabian Ullrich, et al.
Journal of Geriatric Oncology (2024) Vol. 15, Iss. 3, pp. 101734-101734
Open Access | Times Cited: 9
Aponermin: First Approval
Sohita Dhillon
Drugs (2024) Vol. 84, Iss. 4, pp. 459-466
Closed Access | Times Cited: 9
Bone marrow inflammation in haematological malignancies
Madelon M.E. de Jong, Lanpeng Chen, Marc H.G.P. Raaijmakers, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 8, pp. 543-558
Closed Access | Times Cited: 9
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma
Tadeusz Kubicki, Dominik Dytfeld, David R. Barnidge, et al.
Blood (2024) Vol. 144, Iss. 9, pp. 955-963
Open Access | Times Cited: 9
Global, regional, and national burden and quality of care of multiple myeloma, 1990–2019
Jiawei Geng, Jianhui Zhao, Rong Fan, et al.
Journal of Global Health (2024) Vol. 14
Open Access | Times Cited: 8
Obesity and myeloma: Clinical and mechanistic contributions to disease progression
Constance Marques-Mourlet, Reagan Di Iorio, Heather Fairfield, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 19
SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
Emily Chu, Jian Wu, Stacey S. Kang, et al.
Current Oncology (2023) Vol. 30, Iss. 9, pp. 7891-7903
Open Access | Times Cited: 18
Anti-BCMA novel therapies for multiple myeloma
Vincenzo Sammartano, Marta Franceschini, Sara Fredducci, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 1, pp. 169-181
Open Access | Times Cited: 17
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
Abhinava K. Mishra, Ashna Gupta, Gunjan Dagar, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1721-1721
Open Access | Times Cited: 16
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
Zhengyu Yu, Hexian Li, Qizhong Lu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Small RNA‐seq and clinical evaluation of tRNA‐derived fragments in multiple myeloma: Loss of mitochondrial i‐tRFHisGTG results in patients' poor treatment outcome
Konstantinos Soureas, M. Papadimitriou, Panagiotis Malandrakis, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1790-1800
Open Access | Times Cited: 7
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 10, pp. e329-e335
Closed Access | Times Cited: 5
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 415-415
Open Access | Times Cited: 15
Liquid biopsy in hematological malignancies: current and future applications
Donatella Talotta, Mohammad Almasri, Chiara Cosentino, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 15
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C. Mo, Andrew J. Yee, Shonali Midha, et al.
eJHaem (2023) Vol. 4, Iss. 3, pp. 792-810
Open Access | Times Cited: 15
Perspectives on the Treatment of Multiple Myeloma
Abdul Rafae, Frits van Rhee, Samer Al Hadidi
The Oncologist (2023) Vol. 29, Iss. 3, pp. 200-212
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top